Clinical trials in diastolic heart failure

Progress in Cardiovascular Diseases

Volumn 47, Issue 6, 2005, Pages 389-395

  Massie, Barry M ^a,b   Fabi, Mary Rose ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LOSARTAN; NEBIVOLOL; PERINDOPRIL; PROPRANOLOL; SPIRONOLACTONE; VERAPAMIL;

AWARENESS; CLINICAL TRIAL; CONFIDENCE INTERVAL; EXERCISE TOLERANCE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERTENSION; LUNG CONGESTION; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PERIPHERAL EDEMA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SYSTOLE; TREATMENT OUTCOME;

EID: 23944479387     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2005.02.005     Document Type: Article

References (32)

1. American Heart Association Heart and Stroke Facts 2004 Available at: http://www.americanheart.org/presenter.jhtml?identifier=3000090
2. D.W. Kitzman, J.M. Gardin, and J.S. Gottdiener Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study Am. J. Cardiol. 87 2001 413 419
3. R.S. Vasan, E.J. Benjamin, and D. Levy Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective J. Am. Coll. Cardiol. 26 1995 1565 1574
4. V.L. Roger, S.A. Weston, and M.M. Redfield Trends in heart failure incidence and survival in a community-based population JAMA 292 2004 344 350
5. K. Hogg, K. Swedberg, and J. McMurray Heart failure with preserved left ventricular systolic function: Epidemiology, clinical characteristics, and prognosis J. Am. Coll. Cardiol. 43 2004 317 327
6. J.S. Rumsfeld, and F.A. Masoudi Sex differences: Implications for heart failure care Eur. Heart J. 25 2004 101 103
7. G. Aurigemma, and W. Gaasch Diastolic heart failure N. Engl. J. Med. 351 2004 1097 1105
8. A. Stromberg, and J. Martensson Gender differences in patients with heart failure Eur. J. Cardiovasc. Nurs. 2 2003 7 18
9. K.W. Dauterman, M. Gheorghiade, and B.M. Massie Heart failure associated with preserved systolic function: A common and costly clinical entity Am. Heart J. 135 1998 S310 S319
10. M.R. Zile, C.F. Baicu, and W.H. Gaasch Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle N. Engl. J. Med. 350 2004 1953 1959
11. D.W. Kitzman Diastolic heart failure in the elderly Heart Fail. Rev. 7 2002 17 27
12. W.J. Remme, and K. Swedberg European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology Eur. J. Heart Fail. 4 2002 11 22
13. J.S. Gottdiener, R.L. McClelland, and R. Marshall Outcome of congestive heart failure in elderly persons: Influence of left ventricular systolic function. The Cardiovascular Health Study Ann. Intern. Med. 137 2002 631 639
14. R.S. Vasan, M.G. Larson, and E.J. Benjamin Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort J. Am. Coll. Cardiol. 33 1999 1948 1955
15. A.A. Elesber, and M.M. Redfield Approach to patients with heart failure and normal ejection fraction Mayo Clin. Proc. 76 2001 1047 1052
16. J.F. Setaro, B.L. Zaret, and D.S. Schulman Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance Am. J. Cardiol. 66 1990 981 986
17. W.S. Aronow, C. Ahn, and I. Kronzon Effect of propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction >40% treated with diuretics plus angiotensin-converting enzyme inhibitors Am. J. Cardiol. 80 1997 207 209
18. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N. Engl. J. Med. 325 1991 293 302
19. E.F. Philbin, and T.A. Rocco Jr Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function Am. Heart J. 134 1997 188 195
20. K.W. Dauterman, A.S. Go, and R. Rowell Congestive heart failure with preserved systolic function in a statewide sample of community hospitals J. Card. Fail. 7 2001 221 228
21. J.G. Warner Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise J. Am. Coll. Cardiol. 33 1999 1567 1572
22. S.A. Hunt ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult 2001 Available at: http://www.acc.org/clinical/ guidelines/failure/hf_index.htm
23. W.J. Remme, and K. Swedberg Guidelines for the diagnosis and treatment of chronic heart failure, task force for the diagnosis and treatment of chronic heart failure. European Society of Cardiology Eur. Heart J. 22 2001 1527 1560
24. B.M. Massie Natriuretic peptide measurements for the diagnosis of "nonsystolic" heart failure: Good news and bad J. Am. Coll. Cardiol. 41 2003 2018 2021
25. M.M. Redfield, R.J. Rodeheffer, and S.J. Jacobsen Plasma brain natriuretic peptide concentration: Impact of age and gender J. Am. Coll. Cardiol. 40 2002 976 982
26. The Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure N. Engl. J. Med. 336 1997 525 533
27. K. Swedberg, M. Pfeffer, and C. Granger Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): Rationale and design. CHARM-Programme Investigators J. Card. Fail. 5 1999 276 282
28. S. Yusuf, M.A. Pfeffer, and K. Swedberg Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial Lancet 362 2003 777 781
29. M.C. Shibata, M.D. Flather, and M. Bohm Study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure. Study (SENIORS) Int. J. Cardiol. 86 2002 77 85
30. M.D. Flather, M.C. Shibata, and A.J. Coats Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur. Heart J. 26 2005 215 225
31. Carson P, Massie BM, McKelvie R, et al for the I-PRESERVE investigators: The irbesartan in heart failure with preserved systolic functional trial: rationale and design. J Cardiac Fail (in press).
32. J.G. Cleland, M. Tendera, and J. Adamus Perindopril for elderly people with chronic heart failure: The PEP-CHF Study Eur. J. Heart Fail. 1 1999 211 217